Common infections will kill millions if drug resistance through misuse of antibiotics is not curbed, says England’s ex-chief medical officer

It kills millions every year, with a potential impact in the near future that could dwarf that of the Covid-19 pandemic but AMR, or antimicrobial resistance, remains a little-known problem outside specialist circles.

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

The AMR Action Fund announced that one of its portfolio companies, UTILITY Therapeutics, Ltd., received approval from the U.S. Food and Drug Administration (FDA) for the antibiotic PIVYA™ (pivmecillinam) for the treatment of uncomplicated UTIs (uUTI).

A new report indicates the world's leading economies have made progress in their efforts to address antimicrobial resistance (AMR) but need to do more to lessen the health and financial impact of the looming public health crisis.